Browsing Tag
Zepbound
33 posts
Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered
Medicare GLP-1 Bridge starts today at $50/month. Wegovy, Zepbound KwikPen and Foundayo are in; Ozempic and Mounjaro are out. Novo and Lilly split the win.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Eli Lilly’s oral GLP-1 Foundayo gains new women’s health angle with menopause weight-loss data
Lilly’s oral GLP-1 now targets menopause-linked weight gain. Read why Foundayo could sharpen the next obesity drug battleground.
Eli Lilly (LLY) reclaims a $1tn valuation as Wall Street bets on its next weight-loss drug
Eli Lilly reclaimed a $1 trillion valuation at a record high as Wall Street prices in retatrutide, its next-gen obesity drug, and the GLP-1 metabolic platform thesis.
Is Eli Lilly (LLY) building the obesity drug supply chain nobody else can easily match?
Lilly’s obesity pipeline needs industrial muscle. Its $4.5bn Indiana bet shows why manufacturing may decide the next GLP-1 race.
Magnum Ice Cream (NYSE: MICC) jumps 10.9% on Blackstone and CD&R takeover talk just five months after the Unilever spinoff
Magnum spun out of Unilever at 7.8 billion euros. Froneri sold at 15 billion. Blackstone and CD&R are watching. The summer ice cream season decides the bid.
Diageo (LSE: DGE) gains 1.5% as insider buying and Q3 recovery momentum extend the turnaround narrative
Diageo's 0.3% Q3 growth was minimal. But it was the first positive print in a year, and the August strategy update is where the real test begins.
Eli Lilly (NYSE: LLY) bets on oral GLP-1 Foundayo and retatrutide to reclaim its $1tn valuation
Eli Lilly (NYSE: LLY) launched Foundayo, the world's first oral GLP-1 for obesity, in April 2026 and reports Q1 earnings April 30. Full pipeline and risk analysis for retail investors.
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.